Arvinas Highlights Vepdegestrant Breast Cancer Data at 2025 SABCS
Arvinas Inc. will present multiple abstracts on vepdegestrant, a PROTAC estrogen receptor degrader, at the 2025 San Antonio Breast Cancer Symposium. The presentations include subgroup analyses from the phase 3 VERITAC-2 trial, circulating tumor DNA biomarker analyses, and early clinical data on combining vepdegestrant with a KAT6 inhibitor. Full abstracts are available online. This information was originally published by Arvinas Inc. via GlobeNewswire.
Arvinas Inc. has announced that multiple abstracts related to vepdegestrant (ARV-471), an investigational PROTAC estrogen receptor degrader, have been accepted for presentation at the upcoming 2025 San Antonio Breast Cancer Symposium (SABCS), scheduled for December 9-12, 2025. The presentations will include subgroup analyses from the phase 3 VERITAC-2 trial comparing vepdegestrant to fulvestrant in ER-positive/HER2-negative advanced breast cancer, circulating tumor DNA biomarker analyses from a phase 1⁄2 study, and early clinical data on the combination of vepdegestrant with the KAT6 inhibitor PF-07248144. The results will be presented at the symposium and full abstracts are available via the SABCS online program. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9580595-en) on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
